Search Results
Your search for ,kEY matches 7151 pages
Showing 6701 - 6750Cancer-Killing Virus Plus Chemotherapy Studied in Recurrent Ovarian Cancer
In 6 out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and 5-year survival is only 27%. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease. Researchers at The Ohio...
Advancing ASCO’s Commitment to Quality to Ensure That Every Patient Receives the Highest Level of Cancer Care
On December 3, 2014, Robert S. Miller, MD, FACP, FASCO, will start his new position as Medical Director of ASCO’s Institute for Quality (iQ). Established in 2012 to oversee the development of clinical practice guidelines, the Quality Oncology Practice Initiative (QOPI), the QOPI Certification...
Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
On this historic year, as ASCO proudly commemorates its 50th anniversary and decades of evolutionary change and growth, it also celebrates the significant progress that has been made against cancer throughout history. ASCO’s anniversary website, CancerProgress.Net, chronicles these achievements and ...
From ‘Clinical Judgment’ to Evidence-Based Medicine: Thoughts on the ASCO/CCO Guideline in Metastatic Castration-Resistant Prostate Cancer
We are witnessing unprecedented progress in the development of therapy for patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has issued 13 approvals since 1996 for agents that have demonstrated an impact on overall survival, pain, or...
FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...
Assessing the Nature of Unplanned Emergency Cancer Care Situations
Unplanned cancer care—emergency department presentations and other unanticipated events—can result in poor outcomes that are potentially preventable. Suzanne Tamang, PhD, Stanford University, Stanford, California, addressed this important issue in her presentation at this year’s Quality Care...
ASH Pairs Hematologists From Developing and Developed Nations for Global Training Program
The American Society of Hematology (ASH) recently announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity ...
ASCO Calls for Major Medicaid Reform to Improve Quality Cancer Care for Low-Income Americans
ASCO issued its new Policy Statement on Medicaid Reform on November 17, which calls for major changes to the program to ensure access to high-quality cancer care for all low-income individuals. The Society’s recommendations call for Medicaid expansion in all 50 states to close coverage gaps,...
New Agents and Novel Targets for Multiple Myeloma
New therapies for multiple myeloma have dramatically improved life expectancy, but despite these advances, 5-year overall survival still remains below 50%. Investigators are in hot pursuit of new therapies that will extend remissions and improve survival. Thus far, monoclonal antibodies,...
Regis Chair for Breast Cancer Research Established
In partnership with the Regis Foundation for Breast Cancer Research, Regis Corporation, a leader in beauty salons and cosmetology, has announced that the Masonic Cancer Center at the University of Minnesota, Minneapolis, has established the Regis Chair for Breast Cancer Research. This milestone...
Palliative Care in 2014
Palliative care expert Diane E. Meier, MD, is the Director of the Center to Advance Palliative Care (CAPC), a national organization devoted to enhancing the number and quality of palliative care programs across the nation. Under her leadership, the number of palliative care programs in the United...
Policy Issues in Molecularly Targeted Therapy: The Science, the Money, the Applications
In the past decade, much new knowledge about the molecular underpinnings of cancer has accumulated, and the array of molecular aberrations in each individual tumor can be assessed through genomic sequencing and other tests. The rationale for and feasibility of developing molecularly targeted...
Moving a Mountain: Crizotinib in ROS1-Rearranged NSCLC
It was thousands of years ago in China. An elderly man was unhappy with the mountain that embraced his seaside village. He would need to walk for hours before he could reach the nearest town. So, as the old fable goes, he set his mind to move the mountain. Every day, he dug up basketfuls of rocks...
ASCO Clinical Expert Statement on Cancer Survivorship Care Planning
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete them, the lack of role clarity, and the lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship Care Planning...
Lung Cancer: Next Frontier for Immunotherapy
Immune checkpoint inhibitors, particularly PD-1 (programmed cell death-1) and PD-L1 (programmed death-ligand 1) inhibitors, are being studied extensively in lung cancer. These agents, alone and in combination, appear to have the potential to change the management of non–small cell lung cancer...
Patients With Chronic Lymphocytic Leukemia Who Progress After Front-line Treatment May Be Candidates for Novel Noncytotoxic Therapies
Although patients who relapse within 3 years of front-line fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) therapy have poor survival when treated with conventional salvage regimens, these patients may be candidates for novel noncytotoxic therapies, according to an analysis of extended...
Breast Health Global Initiative Tackles Third-World Health Care
Benjamin O. Anderson, MD, is the Director of the Breast Health Global Initiative (BHGI) and surgical oncologist and Director of the Breast Health Clinic at the University of Washington in Seattle. The ASCO Post recently spoke with Dr. Anderson about the conceptual framework of the...
Victor Filadora, MD, MBA, Named Chief of Clinical Services at Roswell Park Cancer Institute
Roswell Park Cancer Institute (RPCI) has named Victor Filadora, MD, MBA, as Chief of Clinical Services. In this new role, Dr. Filadora, an anesthesiologist first appointed to the Institute’s medical staff in 2003, is responsible for managing the comprehensive cancer center’s Ambulatory Services,...
Cancer.Net Launches PRE-ACT Patient Clinical Trial Education Program
Clinical trials are the key to driving advances in the prevention, diagnosis, and treatment of cancer, yet, it is estimated that only about 5% of patients with cancer participate in clinical trials. That is why Cancer.Net, ASCO’s patient-facing educational website, has teamed up with Neal Meropol,...
FDA’s Janet Woodcock, MD, Receives Lifetime Achievement Award From the Institute for Safe Medication Practices
Janet Woodcock, MD, Director of the U.S. Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, has been awarded the Institute for Safe Medication Practices Lifetime Achievement Award, which recognizes “an individual who has had a significant career history of making...
Vitamin D Protects Against Colorectal Cancer by Boosting the Immune System
A study by investigators at Dana-Farber Cancer Institute has demonstrated that vitamin D can protect some people with colorectal cancer by heightening the immune system’s vigilance against tumor cells. The research, released earlier this month by the journal Gut, shows a link between vitamin D and...
Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
The phase III global ASPIRE trial documented an “unprecedented” duration of remission in relapsed multiple myeloma patients receiving carfilzomib (Kyprolis) plus a standard-of-care doublet, according to Keith Stewart, MB, ChB, Professor of Medicine at the Mayo Clinic in Scottsdale, Arizona, who...
Growing Support Group for Epithelioid Hemangioendothelioma Spins the ‘Wheel of Hope’
Two years ago, my son was diagnosed with the rare vascular sarcoma epithelioid hemangioendothelioma, on which there is incredibly little reseach and knowledge (see here for more on this rare cancer). PubMed revealed a “characteristic” description: unpredictable behavior, no correlation with...
Adding Sargramostim to Ipilimumab Improved Overall Survival Among Patients With Unresectable Stage III or IV Melanoma
Patients with unresectable stage III or IV melanoma treated with ipilimumab (Yervoy) plus sargramostim (Leukine) had longer overall survival and less toxicity than did those treated with ipilimumab alone, according to a phase II randomized clinical trial conducted by the Eastern Cooperative...
Transitioning From Volume to Value in Cancer Care
In an oncology health-care system that is increasingly changing its delivery and payment models, how do busy oncologists successfully bridge the transition from a volume- to value-based, patient-centric model? This, and other topics on value fueled a robust discussion at the Association of...
New Choosing Wisely List, Leukemia Quick-Takes From ASH
Nearly 5,000 scientific abstracts were presented at the 2014 American Society of Hematology (ASH) Annual Meeting and Exhibition in San Francisco. Along with our targeted coverage of the meeting’s key newsmakers, The ASCO Post provides you with these brief reports of other interesting...
Expert Point of View: Matthew J. Ellis, MB, BChir, PhD
Matthew J. Ellis, MB, BChir, PhD, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, commented on endocrine resistance and the potential of the four-gene panel for assessing resistance for The ASCO Post. Endocrine response and resistance is a research focus...
Four-Gene Panel Predicts Response to Letrozole
At the 2014 San Antonio Breast Cancer Symposium, a research team led by Michael Dixon, MD, of Western General Hospital in Edinburgh, shed light on the development of endocrine resistance and presented a four-gene messenger RNA (mRNA) profile that can predict response to letrozole with a high degree ...
ASCO Names Advance of the Year, Reviews Top Research Trends
In just a year’s time, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), treatments that are highly effective and far easier for patients to tolerate. These therapies are a major step forward, bringing renewed hope to nearly 120,000 people living with CLL...
Cornerstone Spotlight: Frank M. Muller, Jr
Frank M. Muller, Jr, the newest member of the Conquer Cancer Foundation (CCF) Cornerstone Planned Giving Society, has a 40-year history of successfully leading investment and high-tech corporations. He served 8 years on active duty in tours to Vietnam. It is rare for him to experience a challenge...
FDA Appoints Robert Califf, MD, Deputy Commissioner for Medical Products and Tobacco
U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, MD, has appointed Robert Califf, MD, as the FDA Deputy Commissioner for Medical Products and Tobacco. Dr. Califf is a leader in cardiology, clinical research, and medical economics, who is currently serving as Vice...
Cancer Genetics: Looking Back, Looking Ahead
At the 2014 San Antonio Breast Cancer Symposium, The ASCO Post sat down with geneticist Mary-Claire King, PhD, for some personal musings about her career and how she might guide young researchers who want to follow in her footsteps. Dr. King is known for a variety of accomplishments in genetics,...
Dr. Howard Fine Named Founding Director of the Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
Howard A. Fine, MD, has been appointed to lead the newly established neuro-oncology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, effective February 2. He will serve as Director of the Brain Tumor Center and Associate Director for Translational Research in the Sandra and...
Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening
Atypical hyperplasia of the breast has “special importance as a predictor of future breast cancer,” according to a special report in The New England Journal of Medicine.1 That special importance is based on the high incidence of atypical hyperplasia—found in around 10% of the 1 million breast...
Physician-Scientist Guido Marcucci, MD, Joins City of Hope
Renowned physician and researcher Guido Marcucci, MD, has joined City of Hope in a key leadership role within the institution’s new Hematologic Malignancies and Stem Cell Transplantation Institute. As Director of the Gehr Family Center for Leukemia Research and as Chief of the Division of...
ASTRO Announces Additions to Management Team
The American Society for Radiation Oncology’s (ASTRO) Board of Directors has announced three additions to the Society’s management team: Emily Wilson has been named Executive Vice President; Dave Adler has been promoted to Vice President of Advocacy; and Anne Hubbard has been promoted to Director...
IOM Report Recommends Guidelines for Sharing Clinical Trial Data
A new report from the Institute of Medicine (IOM) provides recommended guidelines about what data should be shared at key times in a clinical trial. In its report, Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk, an IOM committee concludes that sharing data is in the public...
Conquer Cancer Foundation Researchers Lead Six Key Studies Featured in Clinical Cancer Advances 2015
Six of the studies featured in the recently released Clinical Cancer Advances 2015: ASCO’s Annual Report on Progress Against Cancer were led by researchers that whom Conquer Cancer Foundation (CCF) funded early in their careers through its signature Young Investigator Award (YIA) and Career...
How Changes to ACGME’s Accreditation Standards Are Affecting Fellowship Training
Two years ago, the Accreditation Council for Graduate Medical Education (ACGME), the nonprofit organization that evaluates and accredits more than 9,000 medical residency programs in the United States, began phasing in implementation of its Next Accreditation System for graduate medical education,...
ASCO Endorsement of ESMO Guidelines on Hereditary Colorectal Cancer Syndromes
In a recent issue of the Journal of Clinical Oncology,1 and as reviewed in this issue of The ASCO Post, an ASCO expert endorsement panel reviewed and endorsed, with minor qualifications, the European Society for Medical Oncology (ESMO) clinical practice guidelines for management of familial/genetic ...
International Society of Geriatric Oncology: At the Forefront of Physician Education and Research Dissemination in Geriatric Oncology
The ASCO Post announces a new department on geriatric oncology to be published on an occasional basis. Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on...
Tailoring Therapy for Diffuse Large B-Cell Lymphoma by Interim PET May Be Problematic
In a study that reflected clinical practice, treatment of diffuse large B-cell lymphoma based on the results of interim positron-emission tomography (PET) was feasible; however, switching PET-positive patients to an alternative treatment still resulted in inferior treatment outcomes, and the...
FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable
Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a negative surgical margin rate exceeding 96%. The study earned a Merit Award at the 2015...
Translational Research: Under Assault From the Bottom Line
One of the disheartening aspects of becoming a senior medical administrator is that you have the opportunity to view the health-care system from two sides. From the Presidential suite, it is clear that there is increasing chaos in health care in the United States, characterized by blowouts of...
Thomas J. Rutherford, MD, PhD, Named Network Physician Director of Cancer Services at Western Connecticut Health Network
Western Connecticut Health Network (WCHN) has named gynecologic oncologist Thomas J. Rutherford, MD, PhD, an expert in the area of ovarian cancer, as the Network Physician Director of Cancer Services. As Director, Dr. Rutherford will create a new model of cancer delivery in the dynamic environment ...
Douglas R. Lowy, MD, Receives Harrington Prize for Innovation in Medicine
The second annual Harrington Prize for Innovation in Medicine has been awarded to oncologist/researcher Douglas R. Lowy, MD, Chief of the Laboratory of Cellular Oncology and Deputy Director of the National Cancer Institute. The Harrington Prize for Innovation in Medicine, established in 2014 by...
Kay Research and Care Center Opens at St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital in Memphis has officially opened the Kay Research and Care Center. The new $198 million center houses the Eric Trump Foundation Surgery and ICU Center, and the Marlo Thomas Center for Global Education and Collaboration. The St. Jude Red Frog Events Proton...
Aged to (Im)Perfection: Age-Related Clonal Hematopoiesis?
Five decades ago, the analysis of metaphase chromosomes in the hematologic malignancies provided our first broad glimpse into the genetic anatomy of a malignant cell. Today, the advent of high-throughput methods such as next-generation sequencing, capable of surveying the entire genome, provides an ...
From ASH 2014: What’s New in the Myeloma Treatment Arsenal?
At the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, attendance at many multiple myeloma sessions outnumbered the room size, as data from studies of novel agents, such as the monoclonal antibodies, and from key trials, such as ASPIRE, drew crowds. The ASCO Post covered...
Key Evidence Gaps and Research Priorities Should Be Addressed So Physicians Can Identify Patients Most Likely to Benefit From Opioids
Key evidence gaps and research priorities must be addressed “so that physicians can recognize patients for whom opioids are most appropriate and use optimal regimens for these patients,” according to the National Institutes of Health (NIH) Pathways to Prevention Workshop final report on the role of ...
